ImmunityBio (NASDAQ:IBRX) Stock Keeps Buy Rating at HC Wainwright

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Thursday, MarketBeat Ratings reports. They presently have a $15.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 63.40% from the company’s current price. HC Wainwright also issued estimates for ImmunityBio’s FY2027 earnings at $0.10 EPS.

Other equities analysts have also recently issued reports about the company. Jefferies Financial Group upped their price objective on ImmunityBio from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday. Piper Sandler reissued an “overweight” rating and set a $16.00 price objective on shares of ImmunityBio in a report on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of ImmunityBio in a research report on Tuesday, October 6th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $16.00.

ImmunityBio Stock Performance

ImmunityBio stock traded down $0.82 during mid-day trading on Thursday, hitting $9.18. 21,430,325 shares of the company traded hands, compared to its average volume of 20,618,859. ImmunityBio has a one year low of $1.95 and a one year high of $12.43. The stock has a market cap of $9.73 billion, a price-to-earnings ratio of -9.46 and a beta of 0.02. The stock has a fifty day moving average price of $8.54 and a 200-day moving average price of $7.96.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The firm had revenue of $51.24 million for the quarter, compared to analysts’ expectations of $49.70 million. Sell-side analysts predict that ImmunityBio will post -0.44 EPS for the current year.

Insiders Place Their Bets

In related news, Director Barry Simon sold 25,000 shares of ImmunityBio stock in a transaction on Monday, October 5th. The shares were sold at an average price of $10.75, for a total value of $268,750.00. Following the sale, the director owned 2,777,788 shares in the company, valued at $29,861,221. The trade was a 0.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Cohen sold 81,056 shares of the business’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $10.50, for a total transaction of $851,088.00. Following the transaction, the director directly owned 100,309 shares in the company, valued at approximately $1,053,244.50. The trade was a 44.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 66.10% of the company’s stock.

Institutional Trading of ImmunityBio

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. raised its position in shares of ImmunityBio by 29.4% in the 2nd quarter. BlackRock Inc. now owns 34,083,262 shares of the company’s stock worth $298,399,000 after acquiring an additional 7,736,819 shares in the last quarter. State Street Corp boosted its stake in ImmunityBio by 20.8% during the second quarter. State Street Corp now owns 21,398,438 shares of the company’s stock worth $187,343,000 after acquiring an additional 3,690,335 shares in the last quarter. Bank of America Corp DE bought a new stake in ImmunityBio during the second quarter worth about $19,125,000. SEB Asset Management AB purchased a new stake in ImmunityBio in the first quarter worth about $18,770,000. Finally, Private Advisor Group LLC increased its stake in shares of ImmunityBio by 923.5% during the first quarter. Private Advisor Group LLC now owns 1,648,556 shares of the company’s stock valued at $12,644,000 after purchasing an additional 1,487,482 shares in the last quarter. 8.58% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: FDA expands ANKTIVA’s label: The FDA approved ANKTIVA in combination with BCG for patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with papillary-only tumors, in addition to the previously covered carcinoma-in-situ population. The broader label significantly increases the drug’s addressable market and commercial potential. FDA Expands ANKTIVA Approval article
• Positive Sentiment: Durable Phase 2/3 results support ANKTIVA: Long-term QUILT-3.032 data showed a 71% complete response rate in 100 patients, median response duration of 26.6 months, and responses lasting beyond 53 months. Among responding patients, three-year cystectomy-free survival was 84%, suggesting many may avoid bladder-removal surgery. ImmunityBio Phase 3 data article
• Positive Sentiment: Analyst support remains favorable: HC Wainwright reaffirmed its Buy rating and raised its FY2027 EPS estimate to $0.10 from $0.07, while maintaining a $15 price target. Jefferies also reportedly lifted its target to $14, indicating analysts see additional upside if ANKTIVA adoption accelerates.
• Neutral Sentiment: Options activity turned unusually active: Traders purchased 26,656 call options, approximately 44% above average volume. This may reflect increased bullish speculation, but it does not guarantee sustained buying in the shares.
• Negative Sentiment: Investors remain cautious despite the clinical breakthrough: IBRX declined as traders appeared to take profits following the FDA-related rally and evaluate whether the expanded approval and strong data can translate into rapid sales growth. The company remains loss-making, and its latest reported quarter missed the consensus EPS estimate.

About ImmunityBio

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune system against cancer and infectious diseases. The company combines cytokine-based therapies, vaccines, cellular therapies and other immune-modulating technologies in an effort to create durable treatment responses.

Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist immune stimulator.